Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Urinary Kallidinogenase in Acute Ischemic Stroke
NCT06211712Recruiting
- Sponsor
- Huashan Hospital
- Start
- Apr 2024
- Primary completion
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in ischemic stroke comparing Human Urinary Kallidinogenase with Placebo (2 arms). Primary endpoints: Alberta Stroke Program Early CT Score at 7 days and Modified Rankin Scale at 90 days. Started Apr 2024; status: recruiting.
02
Drugs
human urinary kallidinogenase + Shuxuening injection
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06211712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06211712.